Holen Sie sich die Stockscreener-App
12.28
3.08%
-0.39
Handel nachbörslich:
12.25
-0.03
-0.24%
Schlusskurs vom Vortag:
$12.67
Offen:
$12.49
24-Stunden-Volumen:
77,056
Relative Volume:
0.40
Marktkapitalisierung:
$267.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.77%
1M Leistung:
-17.25%
6M Leistung:
+22.31%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.00
$12.66
1-Wochen-Bereich:
$11.51
$13.58
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
12.28 | 275.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-12 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-07 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Aardvark Therapeutics announces leadership appointments - marketscreener.com
Aardvark Therapeutics Launches Dermatology Unit, Names Bryan Jones as Ardia CEO - marketscreener.com
Aardvark Therapeutics, Inc. Announces Appointment of Executive, Effective February 9, 2026 - marketscreener.com
Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline - Nasdaq
Aardvark Therapeutics Appoints Derrick Li as Chief Business Officer; Gives CFO Nelson Sun Additional Role of COO - marketscreener.com
Aardvark Launches Ardia Dermatology Unit, Realigns Leadership - TipRanks
Aardvark Therapeutics Announces Leadership Appointments - Bitget
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer - The Manila Times
Aardvark creates Ardia to develop psoriasis and severe skin treatments - Stock Titan
Aardvark Therapeutics' (AARD) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Aardvark Expands PWS Phase 3 Trial to Younger Children - TipRanks
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility - TradingView
Aardvark Therapeutics Announces FDA Submission and IRB - GlobeNewswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Undervalued Obesity Innovator: Justifying a Buy on Aardvark’s Dual Rare-Disease and Mainstream Metabolic Opportunity - TipRanks
HC Wainwright Reiterates "Buy" Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Trading 12% HigherTime to Buy? - MarketBeat
Insider Stock Buying Reaches US$875.0k On Aardvark Therapeutics - 富途牛牛
B.Riley initiates coverage on Aardvark Therapeutics stock with Buy rating - Investing.com Nigeria
Smart Money: Does Aardvark Therapeutics Inc have declining or rising EPSCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
Ten new option listings and two option delistings on January 22nd - TipRanks
Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target - TipRanks
Market Outlook: Can Aardvark Therapeutics Inc expand its profit marginsJuly 2025 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28% - Yahoo Finance
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher – Time to Buy? - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% HigherTime to Buy? - MarketBeat
Treasury Yields: How Aardvark Therapeutics Inc stock compares to growth peersJuly 2025 Summary & Long-Term Capital Growth Ideas - Bộ Nội Vụ
RSI Check: Can Aardvark Therapeutics Inc stock rebound after recent weaknessMarket Activity Summary & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Aardvark Therapeutics updates investor presentation on hunger therapies - TipRanks
Aardvark Therapeutics, Inc Updates Corporate Presentation - TradingView — Track All Markets
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com
What risks investors should watch in Aardvark Therapeutics Inc. stockBull Run & Safe Capital Growth Tips - ulpravda.ru
Can Aardvark Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Comprehensive Market Scan Insights - Улправда
Will Aardvark Therapeutics Inc. stock deliver consistent dividendsPortfolio Return Report & AI Powered Buy/Sell Recommendations - Улправда
Fed Watch: How Aardvark Therapeutics Inc. stock trades during market volatility2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Nasdaq Moves: How Aardvark Therapeutics Inc. stock trades during market volatilityQuarterly Portfolio Summary & Technical Buy Zone Confirmation - Улправда
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):